In patients with microsatellite instability (MSI)-high mismatch repair (MMR)-deficient metastatic colorectal cancer, front-line pembrolizumab significantly improves progression-free survival (PFS) but not overall survival (OS) compared with front-line chemotherapy, according to final results from the phase 3 KEYNOTE-177 trial.
“These data confirm pembrolizumab [Keytruda, Merck] as standard of care in the first-line treatments of patients with microsatellite instability–high